Skip to Main Content

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of cherries and chocolate — and get started. Meanwhile, do keep us in mind if you hear anything interesting. Have a smashing day …

GlaxoSmithKline (GSK) hopes to revamp drug discovery with a $300 million bet on genetics by buying a stake in 23andMe, Reuters writes. The deal provides the drug maker with exclusive access to the vast DNA database it hopes will help unlock new treatments for a range of diseases. 23andMe, which is backed by Google, has more than 5 million customers, 80 percent of whom have opted in to participate in research; it also has a trove of information about the links between genes and disease. The first project will focus on an experimental Glaxo pill for Parkinson’s disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!